Page 105 - Advanced echocardiography in characterization and management of patients with secondary mitral regurgitation

MR grade at 30 days
Effective regurgitant ori- fice area (cm2)
Regurgitant volume (mL/ beat)
Regurgitant fraction (%)
Left ventricular measures
LV end-systolic diameter (cm)
LV end-diastolic diameter (cm)
LV end-systolic volume (mL)
LV end-diastolic volume (mL)
Total stroke volume (mL)
LV end-systolic volume index (mL/m2)
LV end-diastolic volume index (mL/m2)
LV ejection fraction (%)
Right ventricular measures
RV fractional area change (%)
RV systolic pres- sure (mmHg)
Tricuspid regurgitation, n/N (%)
(0) None
(1+) Mild
(2+) Moderate
(3+) Moderate to Severe (4+) Severe
Grade 0 or 1+
0.40 ± 0.16 (189) 28.2 ± 14.7 (78) 37.2 ± 12.9 (77)
5.3 ± 0.9 (199)
6.2 ± 0.7 (199)
133.2 ± 57.5 (188)
191.0 ± 69.4 (188)
57.7 ± 20.5 (188) 69.1 ± 27.6 (188)
99.1 ± 32.5 (188) 31.4 ± 8.9 (188)
32.43 ± 8.24 (131) 42.2 ± 13.4 (162)
4/197 (2.0) 168/197 (85.3) 23/197 (11.7) 2/197 (1.0) 0/197 (0)
Grade 2+
0.43 ± 0.13 (53) 28.2 ± 23.2 (26) 38.5 ± 15.1 (26)
5.3 ± 0.8 (53)
6.2 ± 0.8 (53)
139.5 ± 57.1 (50)
199.1 ± 70.6 (50)
59.5 ± 24.2 (50) 76.0 ± 32.0 (48)
107.8 ± 38.7 (48) 31.1 ± 9.6 (50)
30.63 ± 8.87 (40) 47.0 ± 13.2 (49)
3/54 (5.6) 45/54 (83.3) 6/54 (11.1) 0/54 (0.0) 0/54 (0.0)
Grade 3+ or 4+ P-value
0.45 ± 0.15 (21) 0.35 33.6 ± 19.3 (14) 0.56 40.9 ± 16.9 (14) 0.65
5.2 ± 0.7 (21) 0.89
6.3 ± 0.6 (21) 0.84
148.8 ± 53.7 (19) 0.46
224.4 ± 67.7 (19) 0.12
75.6 ± 27.0 (19) 0.003 78.1 ± 28.3 (19) 0.18
117.0 ± 32.1 (19) 0.04 34.4 ± 9.2 (19) 0.35
34.09 ± 8.06 (14) 0.33 47.9 ± 15.5 (18) 0.04 0.79
1/20 (5.0) 16/20 (80.0) 3/20 (15.0) 0/20 (0.0) 0/20 (0.0)
Data presented as mean ± SD (n) or n/N (%). CH = chamber; LV = left ventricular; RV = right ventricular; MV = mitral valve; PM = papillary muscl
Impact of mitral valve geometry on all-cause death or HFH at 24 months
In the entire patient population, larger baseline anteroposterior and intercommissural mitral annular diameters were the only mitral valve anatomic parameters that were significantly associated with the composite risk of death or HFH at 24 months (Table 4). Severe MR, moderate or greater TR and increasing mitral EROA and RVSP were
103
Ch 5